Alnylam Pharmaceuticals ALNY Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's total liabilities & equity?
- Alnylam Pharmaceuticals (ALNY) reported total liabilities & equity of $5.56B in Q2 2026.
- How has Alnylam Pharmaceuticals's total liabilities & equity changed year-over-year?
- Alnylam Pharmaceuticals's total liabilities & equity increased by 21.7% year-over-year, from $4.57B to $5.56B.
- What is the long-term trend for Alnylam Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's total liabilities & equity has grown at a 7.8% compound annual growth rate (CAGR), from $3.41B to $4.97B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.